This invention is a new and simple method for the identification of active versus latent matrix metalloprotease enzymes (MMPs) in tissue.
Technology Summary
MMPs are involved in tumor progression and therefore are targets for anti-cancer drug therapies. However, most drug therapies directed at inhibition of MMPs have failed because there is no reliable biomarker to determine MMP activity in tissue.
Using differential specific antibodies targeted to the biomarker of interest, WSU researchers have developed a method to identify whether MMPs are active or in a latent phase. MMP’s that are in the active phase cleave the protein Galectin-3, which is associated with tumor progression. This technology consists of antibodies that recognize the cleaved and non-cleaved Galectin-3, thereby allowing determination of whether or not active MMPs are present.
Market Opportunities
Reliable diagnostic tool to monitor MMP activity for clinical trials of MMP inhibitors.
- Can be applied to current antibody testing platforms, including ELISA, histochemistry, etc., in order to quickly prescreen clinical trial candidates
- Help to revive failed compounds in past MMP inhibitor clinical trials
- Help to identify the best candidates for new clinical trials for MMP inhibitor compounds
Stage of Development
Pre-Clinical
Patent Status
Issued US Patent 8,349,579
References & Publications
Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A. Galectic-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res. 2007 Dec 15;67(24):11760-8.
